Fitness Trackers Aren't Accurate For People With Obesity
By Dennis Thompson HealthDay Reporter

WEDNESDAY, June 25, 2025 — Fitness trackers aren’t accurately assessing the physical activity of people with obesity, a new study argues.
Differences in walking gait, speed, energy burn and other factors mean that folks with excess weight aren’t getting an accurate read from their devices, researchers wrote in the journal Scientific Reports.
“People with obesity could gain major health insights from activity trackers, but most current devices miss the mark,” senior researcher Nabil Alshurafa, an associate professor of behavioral medicine at Northwestern University Feinberg School of Medicine in Chicago, said in a news release.
Alshurafa’s team has developed a new algorithm that enables smartwatches to more accurately monitor the calories burned by people with obesity, researchers said.
Lab tests show that the new algorithm achieves over 95% accuracy in real-world situations, the study says.
“Without a validated algorithm for wrist devices, we’re still in the dark about exactly how much activity and energy people with obesity really get each day — slowing our ability to tailor interventions and improve health outcomes,” Alshurafa said.
Alshurafa said he was motivated to create the algorithm after going to an exercise class with his mother-in-law, who has obesity.
“She worked harder than anyone else, yet when we glanced at the leaderboard, her numbers barely registered,” Alshurafa said. “That moment hit me: fitness shouldn’t feel like a trap for the people who need it most.”
Current algorithms used by fitness trackers were built for people without obesity, Alsurafa explains.
Hip-held trackers often misread energy burn because people with excess weight walk with a different gait and wear the devices at a tilt, researchers said. Wrist-worn devices offer better accuracy, but haven’t been rigorously tested and calibrated for people with obesity.
The team tested their new algorithm against 11 other state-of-the-art methods for estimating exertion, using research-grade fitness trackers and wearable cameras to catch every moment when wrist sensors misread calorie burn.
In one group, 27 people wore a fitness tracker and a mask that calculates energy burn based on the amount of oxygen inhaled and carbon dioxide exhaled.
In another group, 25 people wore a fitness tracker and body camera during their daily activities, the study says.
Alshurafa also had people perform standard exercises modified to take their weight into account — for example, wall pushups as opposed to floor pushups.
“Many couldn’t drop to the floor, but each one crushed wall-pushups, their arms shaking with effort,” Alshurafa said, “We celebrate ‘standard’ workouts as the ultimate test, but those standards leave out so many people. These experiences showed me we must rethink how gyms, trackers and exercise programs measure success — so no one’s hard work goes unseen.”
The next step is to deploy an activity-monitoring app that uses the new algorithm for Apple- and Android-powered smartwatches, researchers said.
The algorithm is open-source, and other researchers are encouraged to test it and build upon it.
“To date, many works have examined the validity of proprietary algorithms from commercial activity monitors,” the research team wrote in their paper. “However, to the best of our knowledge, none of them have published an open-source algorithm that others can replicate using raw data obtained from commercially available wrist-worn sensing devices.”
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-06-26 00:00
Read more

- 2,770 Cases of Arboviral Disease Reported in 48 States and D.C. in 2023
- Building Strength May Take Less Exercise Than You Think
- Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrated A1C Reduction and a Safety Profile Consistent with Daily Insulin in Multiple Phase 3 Trials
- Senate Grills CDC Nominee Susan Monarez on Agency Cuts
- FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis
- Cystic Fibrosis: Symptoms, Treatments, Causes & More
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions